Drug details

Zepzelca (lurbinectedin for injection)

type of Antineoplastics, Alkylating

Zepzelca (lurbinectedin) is an alkylating drug used to treat adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

This drug may have the following side effects:

• myelosuppression, and
• liver toxicity

The following drugs are related to Zepzelca, either as a replacement or used together:

• Abraxane (albumin-bound paclitaxel for injectable suspension)
• Alecensa (alectinib capsules)
• Alimta (pemetrexed)
• Alunbrig (brigatinib tablets)
• Tabrecta (capmatinib tablets)
• Zykadia (ceritinib hard-gelatin capsules)
• Xalkori (crizotinib)
• Taxotere (docetaxel for injection)
• Gemzar (gemcitabine hcl)
• Yervoy (ipilimumab injection)
• Keytruda (pembrolizumab for injection)
• Lorbrena (lorlatinib tablets)
• Pepaxto (melphalan flufenamide for injection for iv use)
• Opdivo (nivolumab injection)
• Paclitaxel Tablets (paclitaxel)